Stonebridge Capital Management Inc. decreased its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 33.5% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 3,065 shares of the medical equipment provider’s stock after selling 1,546 shares during the period. Stonebridge Capital Management Inc.’s holdings in Zimmer Biomet were worth $375,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Longview Partners Guernsey LTD raised its stake in shares of Zimmer Biomet by 17.7% during the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after purchasing an additional 1,128,973 shares in the last quarter. Koch Industries Inc. raised its stake in Zimmer Biomet by 49,697.3% in the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after acquiring an additional 1,038,674 shares during the period. Alyeska Investment Group L.P. raised its stake in Zimmer Biomet by 249.3% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock valued at $119,417,000 after acquiring an additional 727,925 shares during the period. Jana Partners LLC raised its stake in Zimmer Biomet by 16.6% in the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after acquiring an additional 662,497 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Zimmer Biomet by 24.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,759,704 shares of the medical equipment provider’s stock valued at $323,134,000 after acquiring an additional 541,102 shares during the period. Hedge funds and other institutional investors own 86.36% of the company’s stock.
Zimmer Biomet Holdings Inc (NYSE:ZBH) traded down $1.47 during midday trading on Tuesday, reaching $115.05. The company had a trading volume of 155,461 shares, compared to its average volume of 1,516,857. Zimmer Biomet Holdings Inc has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The firm has a market capitalization of $23,565.84, a PE ratio of 12.93, a P/E/G ratio of 2.04 and a beta of 1.08. The company has a quick ratio of 0.83, a current ratio of 1.52 and a debt-to-equity ratio of 0.76.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, hitting the consensus estimate of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The business had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same quarter last year, the firm posted $2.14 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. sell-side analysts predict that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were paid a $0.24 dividend. The ex-dividend date was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 10.65%.
ZBH has been the topic of a number of research analyst reports. SunTrust Banks set a $136.00 price target on Zimmer Biomet and gave the company a “buy” rating in a research note on Wednesday, November 1st. Piper Jaffray Companies cut Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research note on Thursday, November 2nd. BMO Capital Markets decreased their price objective on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating on the stock in a report on Thursday, November 2nd. Morgan Stanley decreased their price objective on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a report on Thursday, November 2nd. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $141.67.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/stonebridge-capital-management-inc-decreases-position-in-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.